Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

747.01 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Hims & Hers Has a Superpower in Healthcare
This isn't just any growth stock. 
Via The Motley Fool
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its... 
Via Benzinga
Exposures Product Safety
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers. 
Via Chartmill
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags. 
Via Benzinga
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition. 
Via Benzinga
Topics Earnings
Exposures Financial
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue... 
Via StockStory
Microsoft, Nvidia, Meta Platforms, and Tesla Helped Propel This Vanguard ETF Over 13% Higher in 9 Days. Here's Why It's Still a Buy Now.
Via The Motley Fool
Topics ETFs World Trade
Exposures Tariff
WeightWatchers Seeks Chapter 11 Bankruptcy Protection As GLP-1 Obesity Drugs Reshape Industry
The company said the reorganization plan would eliminate $1.15 billion in debt from its balance sheet 
Via Stocktwits
Topics Bankruptcy
Exposures Financial Legal
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now... 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Exposures Product Safety
Eli Lilly Stock Is Sliding Tuesday: What's Going On?
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug... 
Via Benzinga
Topics Government
Exposures Political
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant? 
Via MarketBeat
Topics Earnings
Exposures Financial
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Via The Motley Fool
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Exposures Political Product Safety Tariff
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
Exposures Product Safety
2 Mega-Cap Stocks with Solid Fundamentals and 1 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Via The Motley Fool
Topics Earnings Economy Government
Exposures Financial Political Supply Chain
Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
The 9 Best Stocks to Buy Now in May (2025)!
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Viking Therapeutics Stock Was Victorious This Week
Via The Motley Fool
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential. 
Via Benzinga
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
Exposures Tariff
US Futures Rise As Apple, Amazon, Airbnb Earnings Boost Market Sentiment: S&P 500 Hits Milestone That's Preceded A 100% Win Rate Since 1956, Says Expert
U.S. stock futures are in the green early Friday, after another winning day for the markets in the regular session on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.